SCHEMBL4074755

SCHEMBL4074755

O=C(/C=N/O)c1cccc(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.57
CES1 P23141 2/20 0.57
PARP1 P09874 1/20 0.53
HDAC6 Q9UBN7 2/20 0.50
HDAC1 Q13547 1/20 0.50
GPR52 Q9Y2T5 1/20 0.48
PLA2G7 Q13093 1/20 0.45
PKM P14618 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
POLB P06746 1/20 0.43
KCNK3 O14649 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074756 1.00 CES2 (0.57) CES2CES1PARP1HDAC6HDAC1
Fluorobenzene SCHEMBL28122683 0.83 ALDH1A1 (0.47) CES2CES1PLA2G7PKMKMT2A
Fluorobenzene SCHEMBL28285720 0.83 ALDH1A1 (0.47) CES2CES1PLA2G7PKMKMT2A
SCHEMBL27757879 0.82 MAOB (0.49) CES2CES1PARP1GPR52PKM
SCHEMBL9122855 0.79 CA12 (0.53) PARP1MAPT
SCHEMBL9122850 0.79 CA12 (0.53) PARP1MAPT
SCHEMBL3056544 0.79 CES2 (0.63) CES2CES1PARP1HDAC6HDAC1
SCHEMBL22715126 0.78 PARP1 (0.53) PARP1KMT2AMEN1SMN1; SMN2CYP1A2
SCHEMBL22715128 0.78 PARP1 (0.53) PARP1KMT2AMEN1SMN1; SMN2CYP1A2
SCHEMBL29472063 0.78 PARP1 (0.53) PARP1KMT2AMEN1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507489-B2 Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
EP-2084162-B1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS INC (US) 2012-09-12 EP disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
EP-2084162-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-08-05 EP disclosed
WO-2008051808-A2 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB CES2 2434/4885CES1 1881/4885PARP1 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.